In MBC, identical p53 mutations were identified in the morphologically distinct carcinomatous and sarcomatous components, suggesting that p53 mutation is an early event and is maintained during tumour progression, supporting the monoclonal origin of both components [82, 83]. Here, TP53 is linked to neoplasm.